Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Investor Day (2017)
11 slides from Coloplast A/s Class B's investor day presentation, 2017
Slide 1: Chronic Care
Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America
Slide 2: Chronic Care represents more than 75% of Coloplast sales and we continue to outgrow the market
Chronic Care represents more than 75% of Coloplast sales and we continue to outgrow the market Chronic Care sales, in DKK Chronic Care reported sales growth vs. market by region, % FY 15/16 >75% FY 15/16 of Coloplast sales 11.4 billion of DKK annual sales #1 Chronic Care global position Europe Other
Slide 3: Our ambition remains to grow faster than the market driven by our 3 strategic themes
Our ambition remains to grow faster than the market driven by our 3 strategic themes Our revenue ambition is to outgrow the market Our strategic themes 5% - 6% 1 4% - 5% 2 3 Market growth - Annual Source: Coloplast Page 3
Slide 4: New product launches and upgrades have contributed significantly to our growth
1 SUPERIOR AND CLINICALLY DIFFERENTIEATED PRODUCTS New product launches and upgrades have contributed significantly to our growth Innovative products Key growth drivers SenSura® Mio Convex Growth driven by SenSura® Mio Convex Win with SenSura® Mio SenSura® Mio Convex capacity issues solved platform
Slide 5: Care and DtC remain a cornerstone in our transition towards a consumer healthcare company
2 UNIQUE CONSUMER RELATIONSHIP Care and DtC remain a cornerstone in our transition towards a consumer healthcare company We continue to expand our Care program … … and have DtC marketing in all key markets Global online marketing … local Consumer marketing program … capabilities and call center … Ca
Slide 6: Continued above market growth rates in US expected through superior products and consumer efforts
3 NEXT LEVEL COMMERCIAL EXECUTION Continued above market growth rates in US expected through superior products and consumer efforts Coloplast sales vs. market growth Key growth drivers 12 month rolling 3x Challenge the market leader in Ostomy Care • Winning in the acute channel 1.5x • Delivering uni
Slide 7: Ostomy Care: Challenge the market leader
3 NEXT LEVEL COMMERCIAL EXECUTION Ostomy Care: Challenge the market leader Winning in the acute channel Delivering unique value proposition for users and hospitals Coloplast Ostomy Care acute market share +2% +3% + Product Patient education ® FY14/15 FY15/16 FY16/17 H1 Continuation of proven IDN str
Slide 8: Continence Care: Make hydrophilics the standard
3 NEXT LEVEL COMMERCIAL EXECUTION Continence Care: Make hydrophilics the standard Hydrophilics becoming the standard Strong performance in rehabs Securing innovative product access and strong patient service Hydrophilics share of Coloplast IC revenues Coloplast NPD share gain in rehabs +6% Secure pa
Slide 9: Solid growth is expected in China - Pacific and Emerging Markets remain key investment areas
3 NEXT LEVEL COMMERCIAL EXECUTION Solid growth is expected in China - Pacific and Emerging Markets remain key investment areas Further solidify position in China Scale up in Pacific and Emerging Markets Japan South Korea Australia China Russia Poland Israel • Stabilized market albeit at lower absolu
Slide 10: Our ambition remains to grow faster than the market driven by our 3 strategic themes
Our ambition remains to grow faster than the market driven by our 3 strategic themes Our revenue ambition is to outgrow the market Our strategic themes 5% - 6% 4% - 5% Market growth - Annual Page 10
Slide 11: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C